AOD-9604
AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.
01Dosing reference
02Mechanism of action
Receptor Binding
AOD-9604 binds to specific receptors on fat cells, mimicking the lipolytic domain of human growth hormone.
Lipolysis Stimulation
It triggers the breakdown of stored fat (lipolysis) and inhibits the formation of new fat cells (lipogenesis).
Metabolic Regulation
Unlike full HGH, it promotes fat metabolism without affecting insulin sensitivity, blood glucose levels, or cell proliferation.
03Human evidence
Demonstrated excellent safety profile and tolerability in obese patients.
Phase II clinical trials involving over 900 patients showed no significant adverse effects, though weight loss efficacy was modest compared to placebo.
No effect on IGF-1 levels or insulin resistance.
Human studies confirmed that AOD-9604 does not increase IGF-1 or alter carbohydrate metabolism, avoiding common HGH side effects.
04Preclinical evidence
Significant reduction in body weight and fat mass in obese mice.
Animal models demonstrated enhanced fat burning, particularly in visceral fat deposits, without affecting lean body mass.
Potential benefits for cartilage repair.
In vitro and animal studies suggest AOD-9604 may promote cartilage regeneration, often researched in combination with hyaluronic acid for osteoarthritis.
05What is known vs. unknown
- Derived from the C-terminal fragment of human growth hormone (amino acids 177-191).
- Specifically targets fat metabolism by increasing lipolysis and decreasing lipogenesis.
- Does not induce insulin resistance or affect blood sugar levels.
- Has an excellent safety profile demonstrated in human clinical trials.
- Emerging research suggests potential applications in joint health and cartilage repair.
- Long-term efficacy for significant weight loss in humans remains debated due to mixed clinical trial results.
- Optimal dosing protocols for joint repair and non-metabolic applications are not fully established.
- The exact receptor mechanism differentiating its action from full HGH is still being elucidated.
06Safety & regulatory context
07Compared with HGH (Human Growth Hormone)
08Appears in protocols
09Glossary
10Knowledge check
11Sources
More in Weight Loss & Metabolism
MOTS-c
MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.
GLP3-RT (Retatrutide)
Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.
SLU-PP-332
SLU-PP-332 is a novel investigational compound known as an 'exercise mimetic' that activates estrogen-related receptors (ERRs). Preclinical research indicates it can enhance endurance, increase fat oxidation, and promote weight loss without altering food intake or requiring physical exercise. It is currently being studied for its potential to treat metabolic disorders and muscle wasting conditions.